The alteration in PS activity has directly been linked to hereditary or acquired (temporary) hypercoagulability. In terms of temporary PS deficiency, many factors affect plasma PS including hypoxia, cancer, and estrogen
containing contraceptive pills. Studies have reported that PS is downregulated in women who use estrogen
based oral contraceptive agents (OCA) leading to high risk of thrombosis. Moreover, the risk of thrombosis increases significantly in obese women who also take estrogen oral contraceptives. The aim of this project is to investigate how estrogen based oral contraceptives and obesity synergize to reduce plasma PS levels.